Feature | May 14, 2014

Study Shows Significant Overall Cost Savings Using Quadripolar System

Comparative effectiveness study shows use of quadripolar technology reduces hospital utilization and lowers overall costs

May 14, 2014 — Data presented during Heart Rhythm 2014 found the use of quadripolar leads reduced the number of hospitalizations by 53 percent when compared to the non-quadripolar group. This hospitalization rate reduction translated into a statistically significant 62 percent reduction in overall costs for both healthcare systems and patients.

The “Hospitalization Rates and Associated Cost Analysis of Quadripolar versus Bipolar CRT-D: a comparative analysis of a single-center prospective Italian registry” presentation included data that demonstrated hospitalization rates for the quadripolar group were lower than the non-quadripolar group, and patients with the St. Jude Medical Quartet quadripolar LV (left ventricular) lead had a 98 percent probability of having lower costs than patients with non-quadripolar leads. The study showed that use of the quadripolar LV lead was associated with significantly reduced hospitalizations specific to the two types of hospitalizations studied: heart failure and LV lead surgical revision.

“These data are compelling evidence as they show a significant cost saving for the healthcare system and patients utilizing the St. Jude Medical quadripolar pacing system,” said Giovanni Forleo, M.D., electrophysiologist at the University Hospital of Tor Vergata in Rome. “This study showed a strong cost benefit, further demonstrating why quadripolar technology is becoming the standard-of-care for patients requiring CRT [cardiac resynchronization therapy].”

The prospective, single-center, observational registry was a first-time evaluation of hospitalization rates and cost reduction following CRT with quadripolar versus non-quadripolar LV leads. Over three years, 198 patients implanted with either a St. Jude Medical Quartet quadripolar LV lead or a non-quadripolar LV lead, were enrolled in the study. The goal of the study was to compare the hospitalization rate related to heart failure and LV lead surgical revisions between the Quartet quadripolar lead and a traditional bipolar lead for cardiac resynchronization therapy defibrillators (CRT-Ds).

“This study provides additional evidence that the quadripolar system improves patient outcomes and reduces healthcare costs,” said Mark D. Carlson, M.D., chief medical officer and vice president of global clinical affairs for St. Jude Medical. “This study is another example of St. Jude Medical’s commitment to investing in disruptive technologies that transform the treatment of expensive epidemic diseases.”

For more information: www.sjm.com

Related Content

iRhythm Technologies, ZIO continuous cardiac monitoring service, myZIO app, irregular heartbeat symptoms, reporting

Image courtesy of iRhythm Technologies

Technology | ECG Monitoring Services| November 19, 2015
iRhythm Technologies Inc. announced the launch of new patient engagement tools to enhance the diagnosis of cardiac...
wearable Holter monitors, iRhythm, ziopatch, zio patch

iRhythm Technologies Zio Patch was among the first of a new generation of simplified, wearable Holter monitors designed to increase ease of use and patient compliance to increase detection of arrhythmias that may lead to stroke.

Feature | Holter Monitoring Systems| November 16, 2015 | Judy Lenane, RN, MHA
One-third of ischemic strokes are classified as cryptogenic.
Medtronic, Micra TPS, Global Clinical Trial, results

Image courtesy of Medtronic

News | Pacemakers| November 11, 2015
 Medtronic plc announced that the Medtronic Micra Transcatheter Pacing System (TPS) was successfully implanted in...
News | Information Technology| November 06, 2015
The American Medical Association (AMA) partnership with MATTER reached a new phase today to enhance support for start
News | Business| November 05, 2015
November 5, 2015 — On Oct.
News | Business| November 04, 2015
C.R. Bard Inc. announced in late September that it has entered into a definitive agreement to acquire Kobayashi...
LivaNova, Platinum, ICD, CRT-D, launch, Europe and Japan

Image courtesy of LivaNova PLC

News | Implantable Cardioverter Defibrillators (ICD)| November 04, 2015
LivaNova PLC, formerly Sorin Group, launched Platinum, a new range of implantable cardiac defibrillators (ICDs) and...
StopAfib.org, atrial fibrillation, AF-related stroke, patient engagement materials

Infographic courtesy of StopAfib.org

News | Stroke| November 03, 2015
In recognition of World Stroke Day, the patient-focused organization StopAfib.org launched a diverse set of materials...
News | Heart Failure| November 02, 2015
Medical device developer Cardionomic Inc. announced that it has received $20 million in Series A financing. Investors...
Boston Scientific, CE Mark, MRI conditional labeling, CRT-Ds, ICDs

X4 CRT-D system image courtesy of Boston Scientific

News | EP Lab| October 30, 2015
Boston Scientific Corp. has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current...
Overlay Init